Abstract
Background
The efficacy of pharmacological treatment in controlling childhood obesity is controversial. We aimed to compare the effects of three types of drug regimens and placebo on generalized and abdominal obesity among obese children and adolescents who did not succeed to lose weight 3 months after lifestyle modification (diet and exercise).
Methods
This triple-masked randomized clinical trial was conducted among 180 participants aged 10–16 years. They were assigned randomly to 4 groups of equal number to receive metformin, fluoxetine, a combination of the two drugs, or placebo. The trial lasted for 12 weeks and participants were followed up for an additional 12-week period.
Results
Overall, 91.1% (n=164) of the enrolled participants completed the trial. After the 12-week trial, the body mass index decreased significantly in all groups receiving medications [approximately −1.2 (0.2) kg/m2, P<0.05]. This decrease was not significant in the placebo group. Waist circumference decreased significantly in the groups receiving metformin [−2.1 (0.4) cm, P=0.03)] as well as in the group receiving a combination therapy of metformin and fluoxetine [−2.5 (0.4) cm, P=0.01)]. In the 24-week follow-up study, these anthropometric indexes were lower than the baseline in the group that had received a combination therapy of metformin and fluoxetine. No serious drug side-effects were reported.
Conclusions
A limited period of such treatment may help weight control, and might be used to encourage those children who have been refractory to weight loss for continuing the non-pharmacological programs. Our findings should be confirmed in future studies with a longer follow-up period.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Ebbeling CB, Pawlak DB, Ludwig DS. Childhood obesity: public-health crisis, common sense cure. Lancet 2002;360:473–482.
Kelishadi R. Childhood overweight, obesity, and the metabolic syndrome in developing countries. Epidemiol Rev 2007;29:62–76.
Kelishadi R, Ardalan G, Gheiratmand R, Gouya MM, Razaghi EM, Delavari A, et al. Association of physical activity and dietary behaviours in relation to the body mass index in a national sample of Iranian children and adolescents: CASPIAN Study. Bull World Health Organ 2007;85:19–26.
Deckelbaum RJ, Williams CL. Childhood obesity: the health issue. Obes Res 2001;9Suppl 4:239S–243S.
Hashemipour M, Kelishadi R, Asgary S, Talaei M, Salek M, Mohammadifard N, et al. Efficacy of herbal mixtures in childhood obesity control. J Ped Neonat 2006;3:1–5
Medeiros-Neto GA. Should drug be used for treating obese children? Int J obse Relat Metab disord 1993;17:363–365.
Molnár D, Török K, Erhardt E, Jeges S. Safety and efficacy of treatment with an ephedrine/caffeine mixture. The first double-blind placebo-controlled pilot study in adolescents. Int J Obes Relat Metab Disord 2000;24:1573–1578.
Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001;107:E55.
Love-Osborne K, Sheeder J, Zeitler P. Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. J Pediatr 2008;152:817–822.
Webb E, Viner R. Should metformin be prescribed to overweight adolescents in whom dietary/behavioural modifications have not helped? Arch Dis Child 2006;91:793–794.
Uli N, Sundararajan S, Cuttler L. Treatment of childhood obesity. Curr Opin Endocrinol Diabetes Obes 2008;15:37–47.
Glueck CJ, Fontaine RN, Wang P, Subbiah MT, Weber K, Illig E, et al. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism 2001;50:856–861.
Charles MA, Eschwege E, Grandmottet P, Isnard F, Cohen JM, Bensoussan JL, et al. Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial. Diabetes Metab Res Rev 2000;16:2–7.
Lord J, Wilkin T. Metformin in polycystic ovary syndrome. Curr Opin Obstet Gynecol 2004;16:481–486.
Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, et al. Effect of metformin on glucagonlike peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001;24:489–494.
Srinivasan S, Ambler GR, Baur LA, Garnett SP, Tepsa M, Yap F, et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab 2006;91:2074–2080.
Fluoxetine and other drugs for treatment of obesity. Med Lett Drugs Ther 1994;36:107–108.
Halford JC, Harrold JA. Neuropharmacology of human appetite expression. Dev Disabil Res Rev 2008;14:158–164.
Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE. Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 2007;67:27–55.
Halford JC, Harrold JA, Lawton CL, Blundell JE. Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity. Curr Drug Targets 2005;6:201–213.
Dastjerdi MS, Kazemi F, Najafian A, Mohammady M, Aminorroaya A, Amini M. An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction. Int J Obes (Lond) 2007;31:713–717.
Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, Guo SS, Wei R, et al. CDC growth charts: United States. Adv Data 2000;314:1–27.
Roberts CK, Chen AK, Barnard RJ. Effect of a short-term diet and exercise intervention in youth on atherosclerotic risk factors. Atherosclerosis 2007;191:98–106.
Kelishadi R, Hashemi M, Mohammadifard N, Asgary S, Khavarian N. Association of changes in oxidative and proinflammatory states with changes in vascular function after a lifestyle modification trial among obese children. Clin Chem 2008;54:147–153.
Kelishadi R, Ardalan G, Gheiratmand R, Majdzadeh R, Hosseini M, Gouya MM, et al. Thinness, overweight and obesity in a national sample of Iranian children and adolescents: CASPIAN Study. Child Care Health Dev 2008;34:44–54.
Cook S, Auinger P, Li C, Ford ES. Metabolic syndrome rates in United States adolescents, from the National Health and Nutrition Examination Survey, 1999–2002. J Pediatr 2008;152:165–170.
Feinstein RA. Physical activity should be promoted at every well-child visit. AAP News 2004;24:120.
Centers for Disease Control and Prevention. http://www.cdc.gov/physicalactivity/everyone/guidelines/children.html (accessed February 24, 2009).
Lucas B. Nutrition in Childhood. In: Mahan LK, Escott-Stumps, eds. Kraue’s Food, Nutrition & Diet Therapy, 10th ed. Saunders: Philadelphia, 2000: 242–245.
Atabek ME, Pirgon O. Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial. J Pediatr Endocrinol Metab 2008;21:339–348.
Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000;85:2767–2774.
Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick DS. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab 2008;93:4299–4306.
Leombruni P, Pierò A, Lavagnino L, Brustolin A, Campisi S, Fassino S. A randomized, double-blind trial comparing sertraline and fluoxetine 6-month treatment in obese patients with Binge Eating Disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1599–1605.
Guimarães C, Pereira LR, Iucif Júnior N, Cesarino EJ, de Almeida CA, de Carvalho D, et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arq Bras Endocrinol Metabol 2006;50:1020–1025.
Marcus C. Pharmacological Treatment of Childhood Obesity. In: Kiess W, Marcus C, Wabitsch M, eds. Obesity in Childhood and Adolescence. Pediatr Adolesc Med, Basel: Karger, 2004: 211–228.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rezvanian, H., Hashemipour, M., Kelishadi, R. et al. A randomized, triple masked, placebo-controlled clinical trial for controlling childhood obesity. World J Pediatr 6, 317–322 (2010). https://doi.org/10.1007/s12519-010-0232-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12519-010-0232-x